Clinical trial
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
NCT01878708 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- July 31, 2013
- Completion date
- February 28, 2017
- Enrollment
- 2 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
refractory t-cell lymphoma, relapsed t-cell lymphoma, t-cell lymphoma